What is the story about?
What's Happening?
Vivos Inc has announced the establishment of a wholly owned subsidiary in India, named Vivos Scientific India LLP, to support its long-term business strategy. The company plans to set up its first international manufacturing center for RadioGel and IsoPet, expand developmental animal testing, and conduct human trials in India. Vivos is seeking approval from the Drug Controller General of India for expanded human trials, which are expected to support its Investigational Device Exemption process with the FDA. The move demonstrates Vivos' commitment to the Indian market and its strategic expansion plans.
Why It's Important?
Vivos Inc's expansion into India marks a significant step in its global growth strategy, potentially opening new markets for its RadioGel and IsoPet products. Establishing a manufacturing center in India could reduce production costs and enhance the company's competitive position in the medical technology sector. The expansion also aligns with India's growing focus on healthcare innovation and could lead to increased collaboration in medical research and development. For Vivos, successful trials and regulatory approvals in India could facilitate its entry into other international markets.
AI Generated Content
Do you find this article useful?
